Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent

INTRODUCTION: Coronary bifurcations are encountered in about 15% to 20% of percutaneous coronary interventions (PCIs). They are considered technically challenging and associated with worse clinical outcomes than nonbifurcation lesions. The BiOSS LIM C is a dedicated bifurcation balloon expandable st...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil, Robert J., Pawłowski, Tomasz, Legutko, Jacek, Lesiak, Maciej, Witkowski, Adam, Gąsior, Mariusz, Kern, Adam, Bil, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455659/
https://www.ncbi.nlm.nih.gov/pubmed/30946377
http://dx.doi.org/10.1097/MD.0000000000015106
_version_ 1783409675734089728
author Gil, Robert J.
Pawłowski, Tomasz
Legutko, Jacek
Lesiak, Maciej
Witkowski, Adam
Gąsior, Mariusz
Kern, Adam
Bil, Jacek
author_facet Gil, Robert J.
Pawłowski, Tomasz
Legutko, Jacek
Lesiak, Maciej
Witkowski, Adam
Gąsior, Mariusz
Kern, Adam
Bil, Jacek
author_sort Gil, Robert J.
collection PubMed
description INTRODUCTION: Coronary bifurcations are encountered in about 15% to 20% of percutaneous coronary interventions (PCIs). They are considered technically challenging and associated with worse clinical outcomes than nonbifurcation lesions. The BiOSS LIM C is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 μm) releasing sirolimus (1.4 μg/mm(2)) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids. CONCLUSION: The aim of the randomized, multicenter, open-label, controlled POLBOS III trial is to compare BiOSS LIM C with limus second-generation drug-eluting stents (DES) in the treatment of non-left main stem coronary bifurcations (ClinicalTrials.gov NCT03548272).
format Online
Article
Text
id pubmed-6455659
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-64556592019-05-29 Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent Gil, Robert J. Pawłowski, Tomasz Legutko, Jacek Lesiak, Maciej Witkowski, Adam Gąsior, Mariusz Kern, Adam Bil, Jacek Medicine (Baltimore) Research Article INTRODUCTION: Coronary bifurcations are encountered in about 15% to 20% of percutaneous coronary interventions (PCIs). They are considered technically challenging and associated with worse clinical outcomes than nonbifurcation lesions. The BiOSS LIM C is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 μm) releasing sirolimus (1.4 μg/mm(2)) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids. CONCLUSION: The aim of the randomized, multicenter, open-label, controlled POLBOS III trial is to compare BiOSS LIM C with limus second-generation drug-eluting stents (DES) in the treatment of non-left main stem coronary bifurcations (ClinicalTrials.gov NCT03548272). Wolters Kluwer Health 2019-04-05 /pmc/articles/PMC6455659/ /pubmed/30946377 http://dx.doi.org/10.1097/MD.0000000000015106 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Gil, Robert J.
Pawłowski, Tomasz
Legutko, Jacek
Lesiak, Maciej
Witkowski, Adam
Gąsior, Mariusz
Kern, Adam
Bil, Jacek
Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent
title Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent
title_full Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent
title_fullStr Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent
title_full_unstemmed Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent
title_short Rationale and design of the randomized, multicenter, open-label, controlled POLBOS 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM C stent
title_sort rationale and design of the randomized, multicenter, open-label, controlled polbos 3 trial aimed to compare regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting bioss lim c stent
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455659/
https://www.ncbi.nlm.nih.gov/pubmed/30946377
http://dx.doi.org/10.1097/MD.0000000000015106
work_keys_str_mv AT gilrobertj rationaleanddesignoftherandomizedmulticenteropenlabelcontrolledpolbos3trialaimedtocompareregulardrugelutingstentsversusthededicatedcoronarybifurcationsirolimuselutingbiosslimcstent
AT pawłowskitomasz rationaleanddesignoftherandomizedmulticenteropenlabelcontrolledpolbos3trialaimedtocompareregulardrugelutingstentsversusthededicatedcoronarybifurcationsirolimuselutingbiosslimcstent
AT legutkojacek rationaleanddesignoftherandomizedmulticenteropenlabelcontrolledpolbos3trialaimedtocompareregulardrugelutingstentsversusthededicatedcoronarybifurcationsirolimuselutingbiosslimcstent
AT lesiakmaciej rationaleanddesignoftherandomizedmulticenteropenlabelcontrolledpolbos3trialaimedtocompareregulardrugelutingstentsversusthededicatedcoronarybifurcationsirolimuselutingbiosslimcstent
AT witkowskiadam rationaleanddesignoftherandomizedmulticenteropenlabelcontrolledpolbos3trialaimedtocompareregulardrugelutingstentsversusthededicatedcoronarybifurcationsirolimuselutingbiosslimcstent
AT gasiormariusz rationaleanddesignoftherandomizedmulticenteropenlabelcontrolledpolbos3trialaimedtocompareregulardrugelutingstentsversusthededicatedcoronarybifurcationsirolimuselutingbiosslimcstent
AT kernadam rationaleanddesignoftherandomizedmulticenteropenlabelcontrolledpolbos3trialaimedtocompareregulardrugelutingstentsversusthededicatedcoronarybifurcationsirolimuselutingbiosslimcstent
AT biljacek rationaleanddesignoftherandomizedmulticenteropenlabelcontrolledpolbos3trialaimedtocompareregulardrugelutingstentsversusthededicatedcoronarybifurcationsirolimuselutingbiosslimcstent

Ejemplares similares